Real-Life Clinical Effectiveness of Razumab® (World’s First Biosimilar Ranibizumab) in Wet AgeRelated Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Retrospective Pooled Analysis
Journal Title: International Journal of Ophthalmology & Eye Science (IJOES) - Year 2018, Vol 6, Issue 4
Abstract
Purpose: To evaluate the effectiveness of Razumab® (world’s first biosimilar ranibizumab; Intas Pharmaceuticals Ltd., India) in Indian patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). Methods: RE-ENACT, a retrospective, multicenter study, analyzed pooled data of patients with wet AMD, DME, and RVO. Patients who had received ≥3 injections of Razumab® between January and August 2016, were included. Endpoints were: improvement in best corrected visual acuity (BCVA, measured by logMAR/Snellen’s chart), decrease in central macular thickness (CMT, measured by Spectral Domain Optical Coherence Tomography), and proportion of patients with intraretinal fluid (IRF) and subretinal fluid (SRF) at Weeks 4, 8 and 12. Results: Of 561 patients included, 348 (62.04%) were men. Mean ± SE BCVA improved from baseline (0.75 ± 0.01) to Week 4 (0.72 ± 0.01, p = 0.0318), attained significance at Week 8 (0.59 ± 0.01, p < 0.0001), which was maintained at Week 12 (0.49 ± 0.01, p < 0.0001). Mean ± SE CMT significantly (p < 0.0001) decreased from baseline (418.47 ± 4.78μm) to Weeks 4 (407.35 ± 4.65μm), 8 (342.10 ± 3.66μm), and 12 (301.17 ± 2.82μm). Proportion of patients with IRF and SRF significantly (p < 0.0001) decreased from baseline to Weeks 4, 8 and 12 (67.02% vs. 48.48%, 42.60%, and 34.22%, respectively for IRF; and 72.37% vs. 48.48%, 37.97%, 31.37%, respectively for SRF). No new safety concerns with biosimilar ranibizumab were observed. Conclusions: Razumab® is effective in reducing macular thickness and improving visual acuity in patients with wet agerelated macular degeneration, diabetic macular edema, and retinal vein occlusion in routine clinical practice. Razumab® demonstrated considerable effectiveness with no new safety concerns.
Authors and Affiliations
Dr. Shashikant Sharma
Keywords
Related Articles
- EP ID EP532977
- DOI 10.19070/2332-290X-1800076
- Views 53
- Downloads 0
Applications of Polymers in Intraocular Drug Delivery Systems
We are entering a new era of ophthalmic pharmacology where new drugs are rapidly being developed for the treatment of anterior and posterior-segment of the eye disease. The pharmacokinetics of drug delivery to the eye re...
Unusual Lesion of the Eyebrow: A Case Report of Chondroid Syringoma
Chondroid syringoma is a rare mixed tumor accounting for only 0.01% of all primary skin tumors [1]. Though it’s very common occurrence is in head and the neck region, involvement of eyelids is extremely rare [2]. These a...
In Office Occlusion of the Tear Punctum using the CPO Electrode
Dry eye syndrome (DES) is a relatively common condition with signs and symptoms varying from light irritation to functional blindness as a result of corneal opacification. The disorder generally occurs in subjects over 4...
Manual Small Incisional Cataract Surgery Learning Curve: Observational Comparison of Three Trainee Training
Purpose: To assess and compare the learning curve of three ophthalmology trainee in their post graduate training for Manual Small Incisional Cataract Surgery (MSICS) over 50 cases each. Methods: The study was done over...
Is Glaucoma an Optic Neuropathy?
Glaucoma is defined as an optic neuropathy implying that nerve fibers are being atrophied in glaucoma. However, there are many distinctive morphological and histological features between the glaucomatous disc and nongla...